Associated Papers
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM et al.
The Lancet. Oncology, 2018
29361470 (PubMed )
Supplement: NIHMS937685-supplement-1.pdf
Select a paper to view details